Abstract: In the heat utilization installation (1) according to the invention several heat sources (2) are included which are provided each with a jet pump (16), (17), (18), (19). The heat sources (2) are connected to a heat carrier circuit system (7) which includes a single, central circulating pump or circulating pump unit (20). The individual jet pumps (16) to (19) are so controlled for the respective heat sources (2), the required operating temperatures with respect to temperature difference between the outlet and inlet and the flow volume are maintained or achieved. With the possibility of independent control of the flow volumes at the various heat sources (2), uniform fluid temperatures as required for a buffer store (22) or heat consumers can be maintained.

Abstract: In the heat utilization installation (1) according to the invention several heat sources (2) are included which are provided each with a jet pump (16), (17), (18), (19). The heat sources (2) are connected to a heat carrier circuit system (7) which includes a single, central circulating pump or circulating pump unit (20). The individual jet pumps (16) to (19) are so controlled for the respective heat sources (2), the required operating temperatures with respect to temperature difference between the outlet and inlet and the flow volume are maintained or achieved. With the possibility of independent control of the flow volumes at the various heat sources (2), uniform fluid temperatures as required for a buffer store (22) or heat consumers can be maintained.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl, andR.sup.5 completes a keto or ester group,and physiologically acceptable salts thereof.

Abstract: 4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,R.sup.2 is hydrogen, C.sub.1 -C.sub.5 - alkyl, --CN, --NH.sub.2, --CH.sub.2 or --CH.sub.2 OH, preferably methyl,R.sup.3 is hydrogen or alkyl, preferably hydrogen,Y is --CO-- or --SO.sub.2 --, andR.sup.4 is an organic radical, orY-R.sup.4 is hydrogen,and physiologically acceptable salts thereof, are circulation-active and effective for improving myocardial contractility, for raising blood pressure, for lowering blood sugar, for reducing mucosal swelling and for controlling the salt and fluid balance.

Abstract: Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, andn represents a number from 1 to 12,and physiologically acceptable salts thereof.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl,R.sup.5 completes a keto or ester group, andR.sup.6 is a direct bond or --CF.sub.2 -- or --CHF--,and physiologically acceptable salts thereof.

Abstract: For the control of coronary diseases and thromboses there are provided the novel compounds ##STR1## in which R.sup.1 is an optionally substituted phenyl or heterocyclic radical,R.sup.2 is a cyano, keto, carboxy, ester or amide group, andX is from 0 to 6,and physiologically acceptable salts thereof.

Abstract: For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, orrepresents a heterocycle from the series pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl optionally mono- to tetrasubstituted by halogen, phenyl or C.sub.1 -C.sub.4 -alkyl orrepresents straight-chain, branched or cyclic alkyl with up to 14 carbon atoms,and their physiologically acceptable salts.

Abstract: 4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,R.sup.2 is hydrogen, C.sub.1 -C.sub.5 -alkyl, --CN, --NH.sub.2, --CH.sub.2 or --CH.sub.2 OH, preferably methyl,R.sup.3 is hydrogen or alkyl, preferably hydrogen,Y is --CO-- or --SO.sub.2 --, andR.sup.4 is an organic radical, orY--R.sup.4 is hydrogen,and physiologically acceptable salts thereof, are circulation-active and effective for improving myocardial contractility, for raising blood pressure, for lowering blood sugar, for reducing mucosal swelling and for controlling the salt and fluid balance.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is optionally substituted aryl or heterocyclic,R.sup.2 is H, NO.sub.2, CN, C.sub.1 -C.sub.8 -alkylsulphonyl, aryl or carboalkoxy,R.sup.3 is alkyl or aryl,R.sup.4 is H or alkyl,X is C.dbd.O or a direct bond, andn is a number from 1 to 20,or physiologically acceptable salts thereof. A synthesis using morpholines or thiomorpholines is also disclosed.

Abstract: 1,4-Dihydropyridine-3-carboxylic acid piperazides of the formula ##STR1## in which R.sup.1 is CN or alkyl, preferably methyl,R.sup.2 is H, CN, NO.sub.2 or preferably carboxyalkyl,R.sup.3 is aryl or heterocyclic, andR.sup.4 is alkyl, cycloalkyl, aryl or an acyl radical,and physiologically acceptable salts thereof, are circulation active. Novel intermediates are also provided.